Omda AS (OMDA) Fair Value & Analysis
Healthcare · NO · Market cap 724M NOK
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 5 days ago
Share price +3.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 35.72 – kr 56.04 · fair‑value band kr 5.32 – kr 8.86 · the kr 38.00 price screens above the kr 7.09 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Omda AS (OMDA) currently trades at kr 38.00, while our model-based Fair Value estimate is kr 7.09 — implying the stock looks roughly 81.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Omda AS generated revenue of 494M NOK at a net margin of -7.3%. Revenue declined 1.7% year over year. Net debt stands at 424M NOK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Omda AS provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally. The company offers laboratory information management systems consisting of Omda ProSang, a blood, cell, and tissue management system; and medical medication solution comprising Omda Cytodose, an oncology medication management solution. It also provides connected healthcare solutions, including Omda Cardio, an ECG and diagnostic storage tool; Omda CIMA, a clinical imaging mobile application; Omda Media, a web-based medical imaging solution; Omda Medimaker, an image management and workflow solution; Omda Picsara, an image management solution; Omda Arcidis, an integrated teleradiology system; Omda Helsemail, a patient data transfer tool; Omda Plutus, an audit and workflow monitoring platform; Omda S7, an e-care communications platform; and Omda XDS, a patient data storage and management solution. In addition, the company offers Omda Fertsoft, a …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Omda AS reported revenue of kr 494M in FY2025 versus kr 329M in FY2021, a compound +10.7%/yr. Reported net income was kr 6.6M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$172.93 | A$23.91 | -86% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $86.03 | $54.47 | -37% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Omda AS (OMDA) undervalued?
What is the fair value of OMDA?
What is the quality score of OMDA?
What is the revenue of Omda AS (OMDA)?
What is the net profit margin of OMDA?
Does Omda AS pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.